In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 151 to 160 of 303

TitleTypeExpected publication date
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidance
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257Technology appraisal guidanceTBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]Technology appraisal guidance
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442Technology appraisal guidanceTBC
Molnupiravir for treating COVID 19 [ID6340]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All